What Avestria Ventures does

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 by Harvard Business School classmates Linda Greub (Managing Partner) and Corinne Nevinny, focused exclusively on early-stage women's health and female-led life science companies. The firm defines women's health as conditions affecting women exclusively (menopause), differently (cardiovascular disease), or disproportionately (Alzheimer's), and seeks evidenced-based businesses using technology or data to improve healthcare quality, access, cost, or patient empowerment. Avestria manages two funds: Fund I closed in June 2021 with 13 portfolio companies and two exits (Alydia Health and Uqora, acquired by Pharmavite), and Fund II closed in July 2024 with nine portfolio companies including Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.

The firm operates with a lean core team of five (Managing Partner, Partner Tracy Dooley MD, Director of Marketing, Legal Counsel, Social Media Director) augmented by a network of 11 Avestria Advisors — medical doctors, scientists, and regulatory experts — plus LP Advisory Committees across funds. Its revenue model follows traditional VC economics: management fees and carried interest from limited partners, with no publicly disclosed fee rates or fund sizes. Avestria sources deals through direct outreach, founder referrals, and ecosystem partnerships, and markets itself via its website, quarterly newsletter, Women's Health Webinar series (launched 2023), and participation in industry conferences including the J.P. Morgan Healthcare Conference. The firm has been featured in Business Insider, Fast Company, Forbes, TechCrunch, NVCA, and Harvard Business School alumni media as a leading female-run VC investing in women's health.

The business is differentiated less by proprietary technology than by thematic focus, network curation, and founding-team operating credibility. Linda Greub's CFA plus life sciences operating experience (Applied Biosystems, VitaPath Genetics, Novartis Diagnostics, Singulex, Raindance) provides institutional-quality diligence infrastructure at emerging-manager scale. The investment thesis is anchored in a documented market gap — only 1% of healthcare VC funding historically flows to women's health companies per PitchBook, and 1.9% of VC went to female founders in 2022 — positioning Avestria as a specialist capturing what it characterizes as overlooked and undervalued opportunities.

Name

Avestria Ventures

Legal name

Avestria Ventures Management, LLC

Website

https://www.avestria.vc

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Avestria Ventures is a San Francisco-based venture capital firm founded in 2019 that invests seed and early-stage capital in women's health and female-led life science companies through two closed funds (Fund I 2021, Fund II 2024).

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Gender Lens / Diversity, Equity & Inclusion (DEI) Funds (FSANAJAM)

Keywords

• Venture capital
• Women's health investing
• Life sciences funding
• Early-stage healthcare
• Female-led startups

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management: Avestria generates revenue through traditional VC fund management structures including management fees and carried interest from fund returns. Fund II was closed in July 2024 and Fund I was closed in June 2021.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Avestria Ventures is a venture capital firm that invests in early-stage women's health and female-led life science companies. The firm manages two funds — Fund I (closed June 2021) and Fund II (closed July 2024) — providing capital, strategic guidance, and access to a network of medical, scientific, and regulatory advisors to portfolio companies developing technology- and data-driven healthcare solutions.

Product overview

Avestria Ventures is a venture capital firm that operates two investment funds (Fund I, closed June 2021, and Fund II, closed July 2024) focused on seeding women's health and female-led life science ventures. The firm defines women's health as conditions affecting women exclusively, differently, or disproportionately. Avestria's portfolio companies include Midi Health (telehealth platform for midlife care), Raydiant Oximetry (fetal monitoring medical device), ViuHealth (real-world evidence platform), and Uqora (urinary health products, acquired by Pharmavite in 2021). The firm's investment strategy focuses on early-stage businesses utilizing technology and data to improve healthcare quality, access, cost, and patient empowerment.

Differentiator

Problem solved

Functional benefit

Products and services

• Avestria Ventures Fund II A venture capital fund investing in early-stage women's health and female-led life science ventures. Portfolio includes Axena Health, Clarified Precision Medicine, ENB Therapeutics, Elucent Medical, May Health, Meet Mae, Novocuff, AngioInsight, and Mercy BioAnalytics.
• Avestria Ventures Fund I A venture capital fund that invested in women's health and life science companies including Alydia Health (exited), AmplifiDx, Antiva Biosciences, AOA Dx, Avation Medical, Curio, Dahlia Biosciences, Genome Medical, Madorra, Midi Health, Raydiant Oximetry, and Uqora (exited).

Quantifiable outcome

• Two successful exits from Fund I (Alydia Health and Uqora acquisition by Pharmavite)
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• The Leaders RheumcoreStrategic or Co-development Partner · 17 January 2024ViuHealth partners with The Leaders Rheum to transform rheumatology care, improving rheumatologists' ability to serve patients and increase virtual care capacity.
• Coral GenomicsminorStrategic or Co-development Partner · 24 March 2021Partnered with DrugViu to help fill the gap in diverse patient data, develop diagnostics, and improve outcomes for minority patients with Inflammatory Bowel Disease.
• Springboard EnterprisescoreStrategic or Co-development PartnerAvestria's Managing Partner Linda Greub serves on Springboard Enterprises' Women's Health Executive Committee, supporting women-led companies in the healthcare sector.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Market position

Strengths5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/AvestriaVC
• LinkedInlinkedin.com/company/avestria-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avestria Ventures